{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T08:02:20Z","timestamp":1789545740729,"version":"build-2803163510"},"reference-count":105,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","geriatriconcology.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.jgo.2026.104151","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T03:24:51Z","timestamp":1789529091000},"page":"104151","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Management of hepatocellular carcinoma in older patients \u2013 An overview"],"prefix":"10.1016","volume":"18","author":[{"given":"Joseph","family":"Dao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananya","family":"Uddanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryant","family":"Morocho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ponnandai","family":"Somasundar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgo.2026.104151_bb0005","doi-asserted-by":"crossref","unstructured":"Rumgay H, Arnold M, Ferlay J, Lesi O, Cabasag CJ, Vignat J. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol n.d.;77:1598\u2013606. doi:https:\/\/doi.org\/10.1016\/j.jhep.2022.08.021.","DOI":"10.1016\/j.jhep.2022.08.021"},{"key":"10.1016\/j.jgo.2026.104151_bb0010","doi-asserted-by":"crossref","unstructured":"Samant H, Amiri HS, Zibari GB. Addressing the worldwide hepatocellular carcinoma: epidemiology, prevention and management. J Gastrointest Oncol n.d.;12:361\u2013373. doi:10.21037\/jgo.2020.02.08.","DOI":"10.21037\/jgo.2020.02.08"},{"key":"10.1016\/j.jgo.2026.104151_bb0015","doi-asserted-by":"crossref","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin n.d.;71:209\u201349. doi:https:\/\/doi.org\/10.3322\/caac.21660.","DOI":"10.3322\/caac.21660"},{"key":"10.1016\/j.jgo.2026.104151_bb0020","doi-asserted-by":"crossref","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin n.d.;74:229\u201363. doi:https:\/\/doi.org\/10.3322\/caac.21834.","DOI":"10.3322\/caac.21834"},{"key":"10.1016\/j.jgo.2026.104151_bb0025","doi-asserted-by":"crossref","unstructured":"Lin L, Yan L, Liu Y, Qu C, Ni J, Li H. The burden and trends of primary liver cancer caused by specific etiologies from 1990 to 2017 at the global, regional, national, age, and sex level: results from the Global Burden of Disease Study 2017. Liver Cancer n.d.;9:563\u201382. doi:https:\/\/doi.org\/10.1159\/000508568.","DOI":"10.1159\/000508568"},{"key":"10.1016\/j.jgo.2026.104151_bb0030","doi-asserted-by":"crossref","unstructured":"Lee HA, Lee S, Lee HL, Song JE, Lee DH, Han S. The efficacy of treatment for hepatocellular carcinoma in elderly patients. J Liver Cancer n.d.;23:362\u201376. doi:10.17998\/jlc.2023.08.03.","DOI":"10.17998\/jlc.2023.08.03"},{"key":"10.1016\/j.jgo.2026.104151_bb0035","doi-asserted-by":"crossref","unstructured":"Chon YE, Park SY, Hong HP, Son D, Lee J, Yoon E. Hepatocellular carcinoma incidence is decreasing in Korea but increasing in the very elderly. Clin Mol Hepatol n.d.;29:120. doi:https:\/\/doi.org\/10.3350\/cmh.2021.0395.","DOI":"10.3350\/cmh.2021.0395"},{"key":"10.1016\/j.jgo.2026.104151_bb0040","unstructured":"USCS Data Visualizations - CDC n.d. https:\/\/gis.cdc.gov\/Cancer\/USCS\/ (accessed June 9, 2026)."},{"key":"10.1016\/j.jgo.2026.104151_bb0045","doi-asserted-by":"crossref","unstructured":"Georgieva M, Xenodochidis C, Krasteva N. Old age as a risk factor for liver diseases: modern therapeutic approaches. Exp Gerontol n.d.;184:112334. doi:https:\/\/doi.org\/10.1016\/j.exger.2023.112334.","DOI":"10.1016\/j.exger.2023.112334"},{"key":"10.1016\/j.jgo.2026.104151_bb0050","doi-asserted-by":"crossref","unstructured":"Lee HA. Management of hepatocellular carcinoma in elderly and adolescent\/young adult populations. J Liver Cancer n.d.;25:52\u201366. doi:10.17998\/jlc.2025.02.28.","DOI":"10.17998\/jlc.2025.02.28"},{"key":"10.1016\/j.jgo.2026.104151_bb0055","doi-asserted-by":"crossref","unstructured":"Riediger CE, L\u00f6ck S, Frohneberg L, Hoffmann R, Kahlert C, Weitz J. Oncological liver resection in elderly \u2013 a retrospective comparative study. Int J Surg n.d.;104:106729. doi:https:\/\/doi.org\/10.1016\/j.ijsu.2022.106729.","DOI":"10.1016\/j.ijsu.2022.106729"},{"key":"10.1016\/j.jgo.2026.104151_bb0060","doi-asserted-by":"crossref","unstructured":"Yamamoto H, Kaibori M, Matsushima H, Kosaka H, Matsui K, Sekimoto M. Efficacy and safety of liver resection in super elderly patients with hepatocellular carcinoma. Asian Pac J Cancer Prev n.d.;24:1089. doi:10.31557\/apjcp.2023.24.3.1089.","DOI":"10.31557\/APJCP.2023.24.3.1089"},{"key":"10.1016\/j.jgo.2026.104151_bb0065","doi-asserted-by":"crossref","unstructured":"Tajiri K, Shimizu Y. Liver physiology and liver diseases in the elderly. World J Gastroenterol n.d.;19:8459\u201367. doi:https:\/\/doi.org\/10.3748\/wjg.v19.i46.8459.","DOI":"10.3748\/wjg.v19.i46.8459"},{"key":"10.1016\/j.jgo.2026.104151_bb0070","doi-asserted-by":"crossref","unstructured":"Cieslak KP, Baur O, Verheij J, Bennink RJ, Gulik TM. Liver function declines with increased age n.d.;18:691\u20136. doi:https:\/\/doi.org\/10.1016\/j.hpb.2016.05.011, HPB.","DOI":"10.1016\/j.hpb.2016.05.011"},{"key":"10.1016\/j.jgo.2026.104151_bb0075","doi-asserted-by":"crossref","unstructured":"Wynne HA, Cope LH, Mutch E, Rawlins MD, Woodhouse KW, James OF. The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology n.d.;9:297\u2013301. doi:https:\/\/doi.org\/10.1002\/hep.1840090222.","DOI":"10.1002\/hep.1840090222"},{"key":"10.1016\/j.jgo.2026.104151_bb0080","doi-asserted-by":"crossref","unstructured":"Le Couteur DG, McLean AJ. The aging liver. Drug clearance and an oxygen diffusion barrier hypothesis. Clin Pharmacokinet n.d.;34:359\u201373. doi:https:\/\/doi.org\/10.2165\/00003088-199834050-00003.","DOI":"10.2165\/00003088-199834050-00003"},{"key":"10.1016\/j.jgo.2026.104151_bb0085","doi-asserted-by":"crossref","unstructured":"Iber FL, Murphy PA, Connor ES. Age-related changes in the gastrointestinal system. Effects on drug therapy. Drugs Aging n.d.;5:34\u201348. doi:https:\/\/doi.org\/10.2165\/00002512-199405010-00004.","DOI":"10.2165\/00002512-199405010-00004"},{"key":"10.1016\/j.jgo.2026.104151_bb0090","doi-asserted-by":"crossref","unstructured":"B\u00e1rcena B, Salamanca A, Pintado C, Mazuecos L, Villar M, Molt\u00f3 E. Aging induces hepatic oxidative stress and nuclear proteomic remodeling in liver from Wistar rats. Antioxidants n.d.;10. doi:https:\/\/doi.org\/10.3390\/antiox10101535.","DOI":"10.3390\/antiox10101535"},{"key":"10.1016\/j.jgo.2026.104151_bb0095","doi-asserted-by":"crossref","unstructured":"Jorquera F, Culebras JM, Gonz\u00e1lez-Gallego J. Influence of nutrition on liver oxidative metabolism. Nutrition n.d.;12:442\u20137. doi:https:\/\/doi.org\/10.1016\/S0899-9007(96)00101-3.","DOI":"10.1016\/S0899-9007(96)00101-3"},{"key":"10.1016\/j.jgo.2026.104151_bb0100","doi-asserted-by":"crossref","unstructured":"Almazroo OA, Miah MK, Venkataramanan R. Drug metabolism in the liver. Clin Liver Dis n.d.;21:1\u201320. doi:https:\/\/doi.org\/10.1016\/j.cld.2016.08.001.","DOI":"10.1016\/j.cld.2016.08.001"},{"key":"10.1016\/j.jgo.2026.104151_bb0105","unstructured":"Ozougwu JC. Physiology of the liver. Int J Res Pharm Biosci n.d.;4:13\u201324."},{"key":"10.1016\/j.jgo.2026.104151_bb0110","doi-asserted-by":"crossref","unstructured":"Cotreau MM, Moltke LL, Greenblatt DJ. The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokinet n.d.;44:33\u201360. doi:https:\/\/doi.org\/10.2165\/00003088-200544010-00002.","DOI":"10.2165\/00003088-200544010-00002"},{"key":"10.1016\/j.jgo.2026.104151_bb0115","doi-asserted-by":"crossref","unstructured":"Schmucker DL, Sanchez H. Liver regeneration and aging: a current perspective. Curr Gerontol Geriatr Res n.d.;526379. doi:https:\/\/doi.org\/10.1155\/2011\/526379.","DOI":"10.1155\/2011\/526379"},{"key":"10.1016\/j.jgo.2026.104151_bb0120","doi-asserted-by":"crossref","unstructured":"Schmucker DL. Age-related changes in liver structure and function: implications for disease? Exp Gerontol n.d.;40:650\u20139. doi:https:\/\/doi.org\/10.1016\/j.exger.2005.06.009.","DOI":"10.1016\/j.exger.2005.06.009"},{"key":"10.1016\/j.jgo.2026.104151_bb0125","doi-asserted-by":"crossref","unstructured":"Gagliano N, Grizzi F, Annoni G. Mechanisms of aging and liver functions. Dig Dis n.d.;25:118\u201323. doi:https:\/\/doi.org\/10.1159\/000099475.","DOI":"10.1159\/000099475"},{"key":"10.1016\/j.jgo.2026.104151_bb0130","doi-asserted-by":"crossref","unstructured":"Teh SH, Christein J, Donohue J, Que F, Kendrick M, Farnell M. Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: model of end-stage liver disease (MELD) score predicts perioperative mortality. J Gastrointest Surg n.d.;9:1207\u201315. doi:https:\/\/doi.org\/10.1016\/j.gassur.2005.09.008.","DOI":"10.1016\/j.gassur.2005.09.008"},{"key":"10.1016\/j.jgo.2026.104151_bb0135","doi-asserted-by":"crossref","unstructured":"Cucchetti A, Ercolani G, Vivarelli M, Cescon M, Ravaioli M, Barba G. Impact of model for end-stage liver disease (MELD) score on prognosis after hepatectomy for hepatocellular carcinoma on cirrhosis. Liver Transpl n.d.;12:966\u201371. doi:https:\/\/doi.org\/10.1002\/lt.20761.","DOI":"10.1002\/lt.20761"},{"key":"10.1016\/j.jgo.2026.104151_bb0140","doi-asserted-by":"crossref","unstructured":"Divo MJ, Martinez CH, Mannino DM. Ageing and the epidemiology of multimorbidity. Eur Respir J n.d.;44:1055\u201368. doi:https:\/\/doi.org\/10.1183\/09031936.00059814.","DOI":"10.1183\/09031936.00059814"},{"key":"10.1016\/j.jgo.2026.104151_bb0145","doi-asserted-by":"crossref","unstructured":"Nishikawa H, Kimura T, Kita R, Osaki Y. Treatment for hepatocellular carcinoma in elderly patients: a literature review. J Cancer n.d.;4:635\u201343. doi:https:\/\/doi.org\/10.7150\/jca.7279.","DOI":"10.7150\/jca.7279"},{"key":"10.1016\/j.jgo.2026.104151_bb0150","doi-asserted-by":"crossref","unstructured":"Reig M, Forner A, Rimola J, Ferrer-F\u00e0brega J, Burrel M, Garcia-Criado \u00c1, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol n.d.;76:681\u201393. doi:https:\/\/doi.org\/10.1016\/j.jhep.2021.11.018.","DOI":"10.1016\/j.jhep.2021.11.018"},{"key":"10.1016\/j.jgo.2026.104151_bb0155","doi-asserted-by":"crossref","unstructured":"Llovet JM, Br\u00fa C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis n.d.;19:329\u201338. doi:https:\/\/doi.org\/10.1055\/s-2007-1007122.","DOI":"10.1055\/s-2007-1007122"},{"key":"10.1016\/j.jgo.2026.104151_bb0160","unstructured":"Maria S, Gaetano LG, Rosanna PT, Rosario L, Elisa M, Antonietta TM. Analysis of BCLC treatment indications. Have BCLC modified our choice of treatment in HCC patients? A retrospective study Hepatogastroenterology n.d.;56:1090\u20134."},{"key":"10.1016\/j.jgo.2026.104151_bb0165","doi-asserted-by":"crossref","unstructured":"Borzio M, Dionigi E, Parisi G, Raguzzi I, Sacco R. Management of hepatocellular carcinoma in the elderly. World J Hepatol n.d.;7:1521\u20139. doi:https:\/\/doi.org\/10.4254\/wjh.v7.i11.1521.","DOI":"10.4254\/wjh.v7.i11.1521"},{"key":"10.1016\/j.jgo.2026.104151_bb0170","doi-asserted-by":"crossref","unstructured":"Brunot A, Le Sourd S, Pracht M, Edeline J. Hepatocellular carcinoma in elderly patients: challenges and solutions. J Hepatocell Carcinoma n.d.;3:9\u201318. doi:https:\/\/doi.org\/10.2147\/JHC.S101448.","DOI":"10.2147\/JHC.S101448"},{"key":"10.1016\/j.jgo.2026.104151_bb0175","article-title":"The impact of comprehensive geriatric assessment on postoperative outcomes in elderly surgery: a systematic review and meta-analysis","volume":"19","author":"Chen","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.jgo.2026.104151_bb0180","doi-asserted-by":"crossref","unstructured":"Welsh TJ, Gordon AL, Gladman JR. Comprehensive geriatric assessment \u2013 a guide for the non-specialist. Int J Clin Pract n.d.;68:290. doi:https:\/\/doi.org\/10.1111\/ijcp.12313.","DOI":"10.1111\/ijcp.12313"},{"key":"10.1016\/j.jgo.2026.104151_bb0185","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.6004\/jnccn.2021.0043","article-title":"NCCN guidelines\u00ae insights: older adult oncology, version 1.2021: featured updates to the NCCN guidelines","volume":"19","author":"Dotan","year":"2021","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.jgo.2026.104151_bb0190","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/bjs.10459","article-title":"Randomized clinical trial of comprehensive geriatric assessment and optimization in vascular surgery","volume":"104","author":"Partridge","year":"2017","journal-title":"Br J Surg"},{"key":"10.1016\/j.jgo.2026.104151_bb0195","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2021.4158","article-title":"Geriatric assessment\u2013driven intervention (GAIN) on chemotherapy-related toxic effects in older adults with cancer: a randomized clinical trial","volume":"7","author":"Li","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jgo.2026.104151_bb0200","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1001\/jamaoncol.2019.4728","article-title":"Communication with older patients with cancer using geriatric assessment: a cluster-randomized clinical trial from the National Cancer Institute Community oncology research program","volume":"6","author":"Mohile","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jgo.2026.104151_bb0205","doi-asserted-by":"crossref","unstructured":"Lee JS, Choi HW, Kim JS, Lee TY, Yoon YC. Update on resection strategies for hepatocellular carcinoma: a narrative review. Cancers (Basel) n.d.;16:4093. doi:https:\/\/doi.org\/10.3390\/cancers16234093.","DOI":"10.3390\/cancers16234093"},{"key":"10.1016\/j.jgo.2026.104151_bb0210","doi-asserted-by":"crossref","unstructured":"Dixon M, Cruz J, Sarwani N, Gusani N. The future liver remnant: definition, evaluation, and management. Am Surg n.d.; 87(2):276\u201386.","DOI":"10.1177\/0003134820951451"},{"key":"10.1016\/j.jgo.2026.104151_bb0215","doi-asserted-by":"crossref","unstructured":"Kishi Y, Abdalla EK, Chun YS, Zorzi D, Madoff DC, Wallace MJ. Three hundred and one consecutive extended right hepatectomies: evaluation of outcome based on systematic liver volumetry. Ann Surg n.d.;250:540\u20138. doi:https:\/\/doi.org\/10.1097\/SLA.0b013e3181b674df.","DOI":"10.1097\/SLA.0b013e3181b674df"},{"key":"10.1016\/j.jgo.2026.104151_bb0220","doi-asserted-by":"crossref","unstructured":"Shoup M, Gonen M, D'Angelica M, Jarnagin WR, DeMatteo RP, Blumgart LH. Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection. J Gastrointest Surg n.d.;7:325\u201330. doi:https:\/\/doi.org\/10.1016\/S1091-255X(02)00370-0.","DOI":"10.1016\/S1091-255X(02)00370-0"},{"key":"10.1016\/j.jgo.2026.104151_bb0225","doi-asserted-by":"crossref","unstructured":"Shindoh J, Tzeng C-WD, Vauthey J-N. Portal vein embolization for hepatocellular carcinoma. Liver Cancer n.d.;1:159\u201367. doi:https:\/\/doi.org\/10.1159\/000343829.","DOI":"10.1159\/000343829"},{"key":"10.1016\/j.jgo.2026.104151_bb0230","doi-asserted-by":"crossref","unstructured":"Entezari P, Toskich BB, Kim E, Padia S, Christopher D, Sher A. Promoting surgical resection through future liver remnant hypertrophy. Radiographics n.d.;42:2166\u201383. doi:https:\/\/doi.org\/10.1148\/rg.220050.","DOI":"10.1148\/rg.220050"},{"key":"10.1016\/j.jgo.2026.104151_bb0235","doi-asserted-by":"crossref","unstructured":"Hung AK, Guy J. Hepatocellular carcinoma in the elderly: meta-analysis and systematic literature review. World J Gastroenterol n.d.;21:12197\u2013210. doi:https:\/\/doi.org\/10.3748\/wjg.v21.i42.12197.","DOI":"10.3748\/wjg.v21.i42.12197"},{"key":"10.1016\/j.jgo.2026.104151_bb0240","doi-asserted-by":"crossref","unstructured":"Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med n.d.;334:693\u2013700. doi:https:\/\/doi.org\/10.1056\/NEJM199603143341104.","DOI":"10.1056\/NEJM199603143341104"},{"key":"10.1016\/j.jgo.2026.104151_bb0245","doi-asserted-by":"crossref","unstructured":"Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology n.d.;33:1394\u2013403. doi:https:\/\/doi.org\/10.1053\/jhep.2001.24563.","DOI":"10.1053\/jhep.2001.24563"},{"key":"10.1016\/j.jgo.2026.104151_bb0250","doi-asserted-by":"crossref","unstructured":"Mittler J, Heinrich S, Koch M, Hoppe-Lotichius M, Hadian A, Weinmann A. Elderly patients with hepatocellular carcinoma benefit from liver transplantation as much as younger ones. Liver Cancer n.d.;12:171\u20137. doi:https:\/\/doi.org\/10.1159\/000528830.","DOI":"10.1159\/000528830"},{"key":"10.1016\/j.jgo.2026.104151_bb0255","doi-asserted-by":"crossref","unstructured":"Shah MB, Villagomez Rubio DA, Orozco G, Desai S, Ancheta A, Gupta M. Outcomes in elderly patients undergoing liver transplantation compared with liver-directed ablative therapy in early-stage hepatocellular carcinoma. J Am Coll Surg n.d.;234:892\u20139. doi:https:\/\/doi.org\/10.1097\/XCS.0000000000000135.","DOI":"10.1097\/XCS.0000000000000135"},{"key":"10.1016\/j.jgo.2026.104151_bb0260","doi-asserted-by":"crossref","unstructured":"Adeniji N, Arjunan V, Prabhakar V, Mannalithara A, Ghaziani T, Ahmed A. Posttransplant outcomes in older patients with hepatocellular carcinoma are driven by non-HCC factors. Liver Transpl n.d.;27:684\u201398. doi:https:\/\/doi.org\/10.1002\/lt.25974.","DOI":"10.1002\/lt.25974"},{"key":"10.1016\/j.jgo.2026.104151_bb0265","doi-asserted-by":"crossref","unstructured":"Winnick AM, Karabicak I, Distant DA. Elderly Transplant Recipients. Principles and Practice of Geriatric Surgery, n.d., p. 1335\u201350. doi:https:\/\/doi.org\/10.1007\/978-1-4419-6999-6_98.","DOI":"10.1007\/978-1-4419-6999-6_98"},{"key":"10.1016\/j.jgo.2026.104151_bb0270","doi-asserted-by":"crossref","unstructured":"Mustian MN, Shelton BA, MacLennan PA, Reed RD, White JA, Eckhoff DE. Ethnic and age disparities in outcomes among liver transplant waitlist candidates. Transplantation n.d.;103:1425\u201332. doi:https:\/\/doi.org\/10.1097\/TP.0000000000002523.","DOI":"10.1097\/TP.0000000000002523"},{"key":"10.1016\/j.jgo.2026.104151_bb0275","doi-asserted-by":"crossref","unstructured":"Ahmed FA, Khan SA, Hafeez MS, Jehan FS, Aziz H. Outcomes in elderly patients undergoing hepatic resection compared to ablative therapy for hepatocellular carcinoma. J Surg Oncol n.d.;128:803\u201311. doi:https:\/\/doi.org\/10.1002\/jso.27369.","DOI":"10.1002\/jso.27369"},{"key":"10.1016\/j.jgo.2026.104151_bb0280","doi-asserted-by":"crossref","unstructured":"Delvecchio A, Conticchio M, Casella A, Ratti F, Gelli M, Anelli FM. Open, laparoscopic liver resection and percutaneous thermal ablation in elderly patients with hepatocellular carcinoma: outcomes and therapeutic strategy. Surg Endosc n.d.:6700\u201310. doi:https:\/\/doi.org\/10.1007\/s00464-024-11269-w.","DOI":"10.1007\/s00464-024-11269-w"},{"key":"10.1016\/j.jgo.2026.104151_bb0285","doi-asserted-by":"crossref","unstructured":"Wang Y, Luo Q, Li Y, Deng S, Wei S, Li X. Radiofrequency ablation versus hepatic resection for small hepatocellular carcinomas: a meta-analysis of randomized and nonrandomized controlled trials. PLoS One n.d.;9:84484. doi:https:\/\/doi.org\/10.1371\/journal.pone.0084484.","DOI":"10.1371\/journal.pone.0084484"},{"key":"10.1016\/j.jgo.2026.104151_bb0290","doi-asserted-by":"crossref","unstructured":"Cho SW, Steel J, Tsung A, Marsh JW, Geller DA, Gamblin TC. Safety of liver resection in the elderly: how important is age? Ann Surg Oncol n.d.;18:1088\u201395. doi:https:\/\/doi.org\/10.1245\/s10434-010-1404-6.","DOI":"10.1245\/s10434-010-1404-6"},{"key":"10.1016\/j.jgo.2026.104151_bb0295","doi-asserted-by":"crossref","unstructured":"Tsujita E, Utsunomiya T, Ohta M, Tagawa T, Matsuyama A, Okazaki J. Outcome of repeat hepatectomy in patients with hepatocellular carcinoma aged 75 years and older. Surgery n.d.;147:696\u2013703. doi:https:\/\/doi.org\/10.1016\/j.surg.2009.10.054.","DOI":"10.1016\/j.surg.2009.10.054"},{"key":"10.1016\/j.jgo.2026.104151_bb0300","doi-asserted-by":"crossref","unstructured":"Santambrogio R, Barabino M, Scifo G, Costa M, Giovenzana M, Opocher E. Effect of age (over 75 years) on postoperative complications and survival in patients undergoing hepatic resection for hepatocellular carcinoma. J Gastrointest Surg n.d.;21:657\u201365. doi:https:\/\/doi.org\/10.1007\/s11605-016-3354-1.","DOI":"10.1007\/s11605-016-3354-1"},{"key":"10.1016\/j.jgo.2026.104151_bb0305","doi-asserted-by":"crossref","unstructured":"Wu FH, Shen CH, Luo SC, Hwang JI, Chao WS, Yeh HZ Liver resection for hepatocellular carcinoma in oldest old patients World J Surg Oncol n.d.;17:1. doi:https:\/\/doi.org\/10.1186\/s12957-018-1541-0.","DOI":"10.1186\/s12957-018-1541-0"},{"key":"10.1016\/j.jgo.2026.104151_bb0310","doi-asserted-by":"crossref","unstructured":"Lee JS, Park DA, Ryoo S, Park J, Choi GH, Yoo JJ. Efficacy and safety of surgical resection in elderly patients with hepatocellular carcinoma: a systematic review and meta-analysis. Gut Liver n.d.;7;18(4):695.","DOI":"10.5009\/gnl230485"},{"key":"10.1016\/j.jgo.2026.104151_bb0315","doi-asserted-by":"crossref","unstructured":"Barrow B, Martin II RC. Microwave ablation for hepatic malignancies: a systematic review of the technology and differences in devices. Surg Endosc n.d.;37:817\u201334. doi:https:\/\/doi.org\/10.1007\/s00464-022-09567-2.","DOI":"10.1007\/s00464-022-09567-2"},{"key":"10.1016\/j.jgo.2026.104151_bb0320","doi-asserted-by":"crossref","unstructured":"Izzo F, Granata V, Grassi R, Fusco R, Palaia R, Delrio P. Radiofrequency ablation and microwave ablation in liver tumors: an update. Oncologist n.d.;24:990\u20131005. doi:https:\/\/doi.org\/10.1634\/theoncologist.2018-0337.","DOI":"10.1634\/theoncologist.2018-0337"},{"key":"10.1016\/j.jgo.2026.104151_bb0325","doi-asserted-by":"crossref","first-page":"541","DOI":"10.6004\/jnccn.2021.0022","article-title":"Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Benson","year":"2021","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.jgo.2026.104151_bb0330","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","author":"Galle","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jgo.2026.104151_bb0335","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/hepr.13892","article-title":"Clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2021 version (5th JSH-HCC guidelines)","volume":"53","author":"Hasegawa","year":"2023","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jgo.2026.104151_bb0340","doi-asserted-by":"crossref","unstructured":"Kemeny N, Fata F. Hepatic-arterial chemotherapy. Lancet Oncol n.d.;2:418\u201328. doi:https:\/\/doi.org\/10.1016\/S1470-2045(00)00419-8.","DOI":"10.1016\/S1470-2045(00)00419-8"},{"key":"10.1016\/j.jgo.2026.104151_bb0345","doi-asserted-by":"crossref","unstructured":"Obi S, Sato S, Kawai T. Current status of hepatic arterial infusion chemotherapy. Liver Cancer (Basel) n.d.;24;4(3):188\u201399.","DOI":"10.1159\/000367746"},{"key":"10.1016\/j.jgo.2026.104151_bb0350","doi-asserted-by":"crossref","unstructured":"Nemoto T, Matsuda H, Nosaka T, Saito Y, Ozaki Y, Hayama R. Comparison of hepatic arterial infusion chemotherapy and sorafenib in elderly patients with advanced hepatocellular carcinoma: a case series. Mol Clin Oncol n.d.;2:1028\u201334. doi:https:\/\/doi.org\/10.3892\/mco.2014.371.","DOI":"10.3892\/mco.2014.371"},{"key":"10.1016\/j.jgo.2026.104151_bb0355","doi-asserted-by":"crossref","unstructured":"Lu H, Gao Y, Xia X, Fu Q, Xiang D. RALOX-HAIC (raltitrexed + oxaliplatin) combined with lenvatinib improves survival and safety in elderly patients with unresectable hepatocellular carcinoma. BMC Cancer n.d.;25:882. doi:https:\/\/doi.org\/10.1186\/s12885-025-14274-x.","DOI":"10.1186\/s12885-025-14274-x"},{"key":"10.1016\/j.jgo.2026.104151_bb0360","doi-asserted-by":"crossref","unstructured":"Lanza C, Ascenti V, Amato G V, Pellegrino G, Triggiani S, Tintori J. All you need to know about TACE: a comprehensive review of indications, techniques, efficacy, limits, and technical advancement. J Clin Med n.d.;14:314. doi:https:\/\/doi.org\/10.3390\/jcm14020314.","DOI":"10.3390\/jcm14020314"},{"key":"10.1016\/j.jgo.2026.104151_bb0365","doi-asserted-by":"crossref","unstructured":"Tang Q, Huang W, Liang J, Xue J. Efficacy and safety of transarterial chemoembolization in elderly patients of advanced hepatocellular carcinoma with portal vein tumor thrombus: a retrospective study. Front Oncol n.d.;11:646410. doi:https:\/\/doi.org\/10.3389\/fonc.2021.646410.","DOI":"10.3389\/fonc.2021.646410"},{"key":"10.1016\/j.jgo.2026.104151_bb0370","doi-asserted-by":"crossref","unstructured":"Cohen MJ, Bloom AI, Barak O, Klimov A, Nesher T, Shouval D. Trans-arterial chemo-embolization is safe and effective for very elderly patients with hepatocellular carcinoma. World J Gastroenterol n.d.;19:2521\u20138. doi:https:\/\/doi.org\/10.3748\/wjg.v19.i16.2521.","DOI":"10.3748\/wjg.v19.i16.2521"},{"key":"10.1016\/j.jgo.2026.104151_bb0375","doi-asserted-by":"crossref","unstructured":"Zhang L, Hong W, Wang Z, Zheng C, Liang B, Shi H. Safety and effectiveness of transarterial chemoembolization in hepatocellular carcinoma patients aged greater versus less than 80 years. Clin Interv Aging n.d.;18:1883\u201392. doi:https:\/\/doi.org\/10.2147\/CIA.S429259.","DOI":"10.2147\/CIA.S429259"},{"key":"10.1016\/j.jgo.2026.104151_bb0380","doi-asserted-by":"crossref","unstructured":"Roth GS, Hernandez O, Daabek N, Brusset B, Teyssier Y, Ghelfi J. Safety and efficacy of transarterial chemoembolization in elderly patients with intermediate hepatocellular carcinoma. Cancers (Basel) n.d.;14:1634. doi:https:\/\/doi.org\/10.3390\/cancers14071634.","DOI":"10.3390\/cancers14071634"},{"key":"10.1016\/j.jgo.2026.104151_bb0385","unstructured":"Zhou Y. Drug-eluting bead transarterial chemoembolization is efficient and well-tolerated in treating elderly Chinese hepatocellular carcinoma patients. Int J Clin Exp Pathol n.d.;11(10):4867."},{"key":"10.1016\/j.jgo.2026.104151_bb0390","doi-asserted-by":"crossref","unstructured":"Braat MN, Samim M, Bosch MAJ, Lam MGEH. The role of ^90Y-radioembolization in downstaging primary and secondary hepatic malignancies: a systematic review. Clin Translat Imaging n.d.;4:283\u201395. doi:https:\/\/doi.org\/10.1007\/s40336-016-0172-0.","DOI":"10.1007\/s40336-016-0172-0"},{"key":"10.1016\/j.jgo.2026.104151_bb0395","doi-asserted-by":"crossref","unstructured":"Riaz A, Gates VL, Atassi B, Lewandowski RJ, Mulcahy MF, Ryu RK. Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization. Int J Radiat Oncol Biol Phys n.d.;79:163\u201371. doi:https:\/\/doi.org\/10.1016\/j.ijrobp.2009.10.062.","DOI":"10.1016\/j.ijrobp.2009.10.062"},{"key":"10.1016\/j.jgo.2026.104151_bb0400","doi-asserted-by":"crossref","unstructured":"Lewandowski RJ, Gabr A, Abouchaleh N, Ali R, Al Asadi A, Mora RA. Radiation segmentectomy: potential curative therapy for early hepatocellular carcinoma. Radiology n.d.;287:1050\u20138. doi:https:\/\/doi.org\/10.1148\/radiol.2018171768.","DOI":"10.1148\/radiol.2018171768"},{"key":"10.1016\/j.jgo.2026.104151_bb0405","doi-asserted-by":"crossref","unstructured":"Mikell JK, Dewaraja YK, Owen D. Transarterial radioembolization for hepatocellular carcinoma and hepatic metastases: clinical aspects and dosimetry models. Semin Radiat Oncol n.d.;30:68\u201376. doi:https:\/\/doi.org\/10.1016\/j.semradonc.2019.08.005.","DOI":"10.1016\/j.semradonc.2019.08.005"},{"key":"10.1016\/j.jgo.2026.104151_bb0410","doi-asserted-by":"crossref","unstructured":"Keane G, Lam M, Braat A, Bruijnen R, Kaufmann N, Jong H, et al. Global practice patterns: an international survey by the Cardiovascular and Interventional Radiology Society of Europe (CIRSE) G. Keane et al.: transarterial radioembolization (TARE) global practice patterns: an. Cardiovasc Intervent Radiol n.d.;47(9):1224\u201336.","DOI":"10.1007\/s00270-024-03768-z"},{"key":"10.1016\/j.jgo.2026.104151_bb0415","doi-asserted-by":"crossref","unstructured":"Lee HN, Hyun D. Complications related to transarterial treatment of hepatocellular carcinoma: a comprehensive review. Korean J Radiol n.d.;24:204\u201323. doi:https:\/\/doi.org\/10.3348\/kjr.2022.0395.","DOI":"10.3348\/kjr.2022.0395"},{"key":"10.1016\/j.jgo.2026.104151_bb0420","doi-asserted-by":"crossref","unstructured":"Karao\u011fullar\u0131ndan \u00dc, G\u00fcm\u00fcrd\u00fcl\u00fc Y, \u00dcsk\u00fcdar O, Odaba\u015f E, G\u00fcler HS, Ge\u00e7kalan C. Efficacy and safety of transarterial radioembolization in elderly patients with hepatocellular carcinoma: a single-center experience. Turk J Gastroenterol n.d.;35:204\u201311. doi:https:\/\/doi.org\/10.5152\/tjg.2024.23155.","DOI":"10.5152\/tjg.2024.23155"},{"key":"10.1016\/j.jgo.2026.104151_bb0425","doi-asserted-by":"crossref","unstructured":"Kim J, Kim JY, Lee JH, Sinn DH, Hur MH, Hong JH. Long-term outcomes of transarterial radioembolization for large single hepatocellular carcinoma: a comparison to resection. J Nucl Med n.d.;63:1215\u201322. doi:https:\/\/doi.org\/10.2967\/jnumed.121.263147.","DOI":"10.2967\/jnumed.121.263147"},{"key":"10.1016\/j.jgo.2026.104151_bb0430","doi-asserted-by":"crossref","unstructured":"Sonbol MB, Riaz IB, Naqvi SAA, Almquist DR, Mina S, Almasri J. Systemic therapy and sequencing options in advanced hepatocellular carcinoma: a systematic review and network meta-analysis. JAMA Oncol n.d.;6:204930. doi:https:\/\/doi.org\/10.1001\/jamaoncol.2020.4930.","DOI":"10.1001\/jamaoncol.2020.4930"},{"key":"10.1016\/j.jgo.2026.104151_bb0435","doi-asserted-by":"crossref","unstructured":"Hou J, Zhang H, Sun B, Karin M. The immunobiology of hepatocellular carcinoma in humans and mice: basic concepts and therapeutic implications. J Hepatol n.d.;72:167\u201382. doi:https:\/\/doi.org\/10.1016\/j.jhep.2019.08.014.","DOI":"10.1016\/j.jhep.2019.08.014"},{"key":"10.1016\/j.jgo.2026.104151_bb0440","doi-asserted-by":"crossref","unstructured":"Sangro B, Sarobe P, Herv\u00e1s-Stubbs S, Melero I. Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol n.d.;18:525\u201343. doi:https:\/\/doi.org\/10.1038\/s41575-021-00438-0.","DOI":"10.1038\/s41575-021-00438-0"},{"key":"10.1016\/j.jgo.2026.104151_bb0445","doi-asserted-by":"crossref","unstructured":"Lyu N, Yi JZ, Zhao M. Immunotherapy in older patients with hepatocellular carcinoma. Eur J Cancer n.d.;162:76\u201398. doi:https:\/\/doi.org\/10.1016\/j.ejca.2021.11.024.","DOI":"10.1016\/j.ejca.2021.11.024"},{"key":"10.1016\/j.jgo.2026.104151_bb0450","doi-asserted-by":"crossref","unstructured":"Egen JG, Ouyang W, Wu LC. Human anti-tumor immunity: insights from immunotherapy clinical trials. Immunity n.d.;52:36\u201354. doi:https:\/\/doi.org\/10.1016\/j.immuni.2019.12.010.","DOI":"10.1016\/j.immuni.2019.12.010"},{"key":"10.1016\/j.jgo.2026.104151_bb0455","doi-asserted-by":"crossref","unstructured":"Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol n.d.;76:862\u201373. doi:https:\/\/doi.org\/10.1016\/j.jhep.2021.11.030.","DOI":"10.1016\/j.jhep.2021.11.030"},{"key":"10.1016\/j.jgo.2026.104151_bb0460","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","article-title":"Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial","volume":"405","author":"Yau","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jgo.2026.104151_bb0465","unstructured":"Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid n.d."},{"key":"10.1016\/j.jgo.2026.104151_bb0470","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/S1470-2045(25)00543-1","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study","volume":"26","author":"Qin","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jgo.2026.104151_bb0475","doi-asserted-by":"crossref","unstructured":"Li D, Toh HC, Merle P, Tsuchiya K, Hernandez S, Verret W. Atezolizumab plus bevacizumab versus sorafenib for unresectable hepatocellular carcinoma: results from older adults enrolled in the IMbrave150 randomized clinical trial. Liver Cancer n.d.;11:558\u201371. doi:https:\/\/doi.org\/10.1159\/000525671.","DOI":"10.1159\/000525671"},{"key":"10.1016\/j.jgo.2026.104151_bb0480","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jgo.2026.104151_bb0485","doi-asserted-by":"crossref","unstructured":"Nikolich-\u017dugich J. The twilight of immunity: emerging concepts in aging of the immune system. Nat Immunol n.d.;19:10\u20139. doi:https:\/\/doi.org\/10.1038\/s41590-017-0006-x.","DOI":"10.1038\/s41590-017-0006-x"},{"key":"10.1016\/j.jgo.2026.104151_bb0490","unstructured":"Gui J, Mustachio LM, Su D-M, Craig RW. Thymus size and age-related thymic involution: early programming, sexual dimorphism, progenitors and stroma. Aging Dis n.d.;3:280\u201390."},{"key":"10.1016\/j.jgo.2026.104151_bb0495","doi-asserted-by":"crossref","unstructured":"Wessels I, Jansen J, Rink L, Uciechowski P. Immunosenescence of polymorphonuclear neutrophils. Sci World J n.d.;10:145\u201360. doi:https:\/\/doi.org\/10.1100\/tsw.2010.14.","DOI":"10.1100\/tsw.2010.14"},{"key":"10.1016\/j.jgo.2026.104151_bb0500","doi-asserted-by":"crossref","unstructured":"Sapey E, Greenwood H, Walton G, Mann E, Love A, Aaronson N. Phosphoinositide 3-kinase inhibition restores neutrophil accuracy in the elderly: toward targeted treatments for immunosenescence. Blood n.d.;123:239\u201348. doi:https:\/\/doi.org\/10.1182\/blood-2013-08-519520.","DOI":"10.1182\/blood-2013-08-519520"},{"key":"10.1016\/j.jgo.2026.104151_bb0505","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1016\/S1470-2045(24)00404-2","article-title":"Management of immune checkpoint inhibitor-associated toxicities in older adults with cancer: recommendations from the International Society of Geriatric Oncology (SIOG)","volume":"26","author":"Eochagain","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jgo.2026.104151_bb0510","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.jgo.2019.10.007","article-title":"Hepatocellular carcinoma in older adults: a comprehensive review by Young International Society of Geriatric Oncology","volume":"11","author":"Arora","year":"2020","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.jgo.2026.104151_bb0515","doi-asserted-by":"crossref","unstructured":"Sears O, Cao Y, Tsung AP. A new standard in liver surgery. JAMA Surg n.d.:160. doi:https:\/\/doi.org\/10.1001\/jamasurg.2025.3076.","DOI":"10.1001\/jamasurg.2025.3076"},{"key":"10.1016\/j.jgo.2026.104151_bb0520","doi-asserted-by":"crossref","unstructured":"Wu MT, He SY, Chen SL, Li LF, he ZQ, Zhu YY Clinical and prognostic implications of pretreatment albumin to C-reactive protein ratio in patients with hepatocellular carcinoma BMC Cancer n.d.;19:538. doi:https:\/\/doi.org\/10.1186\/s12885-019-5747-5.","DOI":"10.1186\/s12885-019-5747-5"},{"key":"10.1016\/j.jgo.2026.104151_bb0525","doi-asserted-by":"crossref","unstructured":"Zhao Y, Huang F, Liu S, Jian L, Xia X, Lin H. Prediction of therapeutic response of unresectable hepatocellular carcinoma to hepatic arterial infusion chemotherapy based on pretherapeutic MRI radiomics and albumin-bilirubin score. J Cancer Res Clin Oncol n.d.;149:5181\u201392. doi:https:\/\/doi.org\/10.1007\/s00432-022-04467-3.","DOI":"10.1007\/s00432-022-04467-3"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406826013056?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406826013056?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:06:05Z","timestamp":1789542365000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406826013056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":105,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2027,1]]}},"alternative-id":["S1879406826013056"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2026.104151","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of hepatocellular carcinoma in older patients \u2013 An overview","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2026.104151","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104151"}}